There are limited data comparing endovascular intervention outcomes in heart failure (HF) patients presenting with symptomatic peripheral artery disease (PAD). Herein we report comparative outcomes (peri-procedural and 1-year major adverse cardiovascular events or MACE) in 1,060 patients (213 HF and 847 non-HF) between 2019-2022 from the multicenter XLPAD Registry (NCT01904851) undergoing non-stent femoropopliteal (FP) and below-the knee (BTK) artery interventions. Mean age 69.36±10.9 years, 27.9% women. Significantly greater proportion in the HF group had hypertension (95.3% vs 89%) and chronic kidney disease (47.9% vs 24.4%), prior myocardial infarction (28.6% vs 16.2%), and critical limb ischemia (CLI) presentation (62.9% vs 54.7%) compared with non-HF (p<0.05 for all comparisons). Equal proportion of interventions were performed in BTK (55% vs 53%) and FP+BTK (45% vs 47%) lesions, respectively in HF and non-HF groups. Mean ABI in both groups was ∼0.8±0.3 due to severe calcification (20.5%), CKD and diabetes mellitus (73%). Chronic total occlusion intervention was the most common lesion (HF 53% vs non-HF 43%; p=0.009). Mean lesion length was 126±106 mm. Conventional balloon angioplasty (81%) and atherectomy (19.4%) were used equally in both groups, except for laser atherectomy use (HF 9.4% vs non-HF 15.2%; p=0.02). Technical success, peri-procedural outcomes, death and MACE at 1-year are shown in Figure 1. HF patients undergoing non-stent intervention for symptomatic PAD have comparable technical success, but significantly worse 1-year mortality and MACE.
No takes yet. Share an insight, caveat, or question.
Singh-Kucukarslan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: